Skip to main content
Clinical Trials/NCT00108225
NCT00108225
Completed
Not Applicable

2895 Effect of a High Protein Diet on the 24-hr Profile of Ghrelin, GH and IGF-1

US Department of Veterans Affairs1 site in 1 country8 target enrollmentJuly 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
US Department of Veterans Affairs
Enrollment
8
Locations
1
Primary Endpoint
IGF-1, GH, Body Composition
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

In this study we tested the hypothesis that an increase in protein content of the diet will result in an increase in the 24-hour integrated circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations and an increase in lean body mass in people with untreated type 2 diabetes.

Detailed Description

Subjects with untreated type 2 diabetes were studied using a randomized crossover design. The study began with an initial two-week observation period. Subjects then were randomly assigned to one arm of the study for 5 weeks. The carbohydrate:protein:fat ratio for the control diet is 55:15:30 whereas for the test diet it is 40:30:30. Following a five-week washout period, subjects were assigned to the other arm of the study. All meals were provided by the SDTU. A six-day rotating meal plan has been devised. At the beginning and end of the 5-week diet period, the subject was admitted to the SDTU (Special Diagnostic and Treatment Unit), was provided with the meals appropriate for the test or control arm of the study, and had blood drawn at various times during a 24-hour period. In addition to measurement of GH and IGF-1, IGF-binding proteins 1 and 3, ghrelin, and body composition were determined.

Registry
clinicaltrials.gov
Start Date
July 2004
End Date
May 2009
Last Updated
11 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • People ages 55 - 75 years old with type 2 diabetes, not receiving oral hypoglycemic agents or insulin.
  • Fasting plasma glucose \< 250 mg/dl (\<14 mM) (tGHb \< 14%).

Exclusion Criteria

  • Subjects will be screened for hematological abnormalities, liver disease, kidney disease, macroalbuminuria (\>300 mg/24 hours), untreated thyroid disease, congestive heart failure, angina, life-threatening malignancies, proliferative retinopathy, diabetic neuropathy, peripheral vascular disease, serious psychological disorders, a body mass index \> 35, and a fasting triglyceride of \> 400 mg/dl.
  • Presence of any of the above will be considered exclusion criteria.

Outcomes

Primary Outcomes

IGF-1, GH, Body Composition

Time Frame: 5 weeks

Study Sites (1)

Loading locations...

Similar Trials